Heart Failure With Preserved Ejection Fraction: Clinical Trials

9 trials for Heart Failure With Preserved Ejection Fraction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 completed, 1 active not recruiting, 1 enrolling by invitation. 9 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Recruiting 3, Completed 2, Active not recruiting 1, Enrolling by invitation 1, Terminated 1, Withdrawn 1
Phase 24Active not recruiting 1, Completed 1, Enrolling by invitation 1, Recruiting 1

Follow Heart Failure With Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure With Preserved Ejection Fraction trials Research Report on Heart Failure With Preserved Ejection Fraction

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
HS235, Placebo - Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Phase 1 / Phase 2Recruiting35Pharma Inc., a GSK company1262026-10-212026-10-30
Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
HS135, Placebo - Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
Phase 1Terminated35Pharma Inc42025-01-232025-09-04
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Dapagliflozin 10 MG [Farxiga] - Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction
Phase 1 / Phase 2Active not recruitingNorthwestern University182024-01-162026-07-30
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
AAV1/SERCA2a - Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Phase 1RecruitingSardocor Corp.102023-08-242023-09-29
Enhancing the Natriuretic Peptide System in HFpEF
MANP, Sacubitril/Valsartan, Oral Placebo - Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Phase 1 / Phase 2Enrolling by invitationHorng Chen602022-11-042026-11-16
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
JK07, Matching Placebo - Heart Failure With Preserved Ejection Fraction
Phase 1WithdrawnSalubris Biotherapeutics Inc2022-10-212023-05-31
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
L-Citrulline, Placebo for L-Citrulline, BH4 - Heart Failure With Preserved Ejection Fraction, Inflammation
Phase 1RecruitingVA Office of Research and Development902021-05-192026-11-16
Developing Oral LT3 Therapy for Heart Failure - HFpEF
liothyronine, Placebo - Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Phase 1 / Phase 2CompletedUniversity of Pennsylvania282020-03-082025-01-08
Physiological Effects of Grape Seed Extract in Diastolic Heart Failure
grape seed extract (MegaNatural BP, Polyphenolics, Inc.) - Diastolic Heart Failure, Hypertensive Heart Disease
Phase 1CompletedUniversity of Michigan152010-10-012017-06-06

Narrower conditions

Heart Failure (4)  ·  Heart Failure, Diastolic (2)  ·  Hypertension, Pulmonary (2)  ·  Renal Insufficiency, Chronic (2)  ·  Euthyroid Sick Syndromes (1)  ·  Fibromatosis, Gingival, 2 (1)  ·  Hypertension (1)  ·  Inflammation (1)  ·  Kidney Diseases (1)

Broader conditions

Cardiovascular Diseases (7)  ·  Heart Diseases (5)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Vascular Diseases (3)  ·  Chronic Disease (2)  ·  Disease Attributes (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Hypertension (2)  ·  Lung Diseases (2)  ·  Male Urogenital Diseases (2)  ·  Renal Insufficiency (2)  ·  Respiratory Tract Diseases (2)  ·  Urogenital Diseases (2)

Interventions

Anthocyanins (1)  ·  Antioxidants (1)  ·  Atorvastatin (1)  ·  Citrulline (1)  ·  Flavonoids (1)  ·  Flavonols (1)  ·  Grape Seed Extract (1)  ·  Polyphenols (1)  ·  Quercetin (1)  ·  Resveratrol (1)  ·  Triiodothyronine (1)  ·  Wine (1)  ·  dapagliflozin (1)  ·  grp protein, Drosophila (1)  ·  sacubitril and valsartan sodium hydrate drug combination (1)

Sponsors

35Pharma Inc (1)  ·  35Pharma Inc., a GSK company (1)  ·  Horng Chen (1)  ·  Northwestern University (1)  ·  Salubris Biotherapeutics Inc (1)  ·  Sardocor Corp. (1)  ·  University of Michigan (1)  ·  University of Pennsylvania (1)  ·  VA Office of Research and Development (1)

Countries

United States (9)

Top investigators

Anne R Cappola, MD,ScM (1)  ·  David W. Wray, PhD (1)  ·  Monique Champagne, M.Sc. (1)  ·  Paul M McKie (1)  ·  Rupal Mehta, MD (1)  ·  Scott L Hummel, MD, MS (1)  ·  Wilson Tang, MD (1)

Results publications

PMID 41546750

NIH funding

I01CX002152 (1), K23HL150236 (1), R61HL146390 (1)